Evidence map›Paper›PMID 36703644›Full record

ArticleDisease markers2023

The Recurrent-Specific Regulation Network of Prognostic Stemness-Related Signatures in Low-Grade Glioma.

Jin Li, Meng Zhou, Dan Huang, Ruoyi Lin, Xiaomei Cui, Shaofeng Chen, Ying Yao, Shuyuan Xian, Siqiao Wang, Qing Fu and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Jin LiDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Meng ZhouDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Dan HuangTongji University School of Medicine, Shanghai 200092, China.
Ruoyi LinTongji University School of Medicine, Shanghai 200092, China.
Xiaomei CuiDepartment of Operating Room, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Shaofeng ChenDepartment of Orthopaedic Surgery, Changhai Hospital, Navy Military Medical University, Shanghai 200433, China.
Ying YaoDepartment of Operating Room, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China.
Shuyuan XianTongji University School of Medicine, Shanghai 200092, China.
Siqiao WangTongji University School of Medicine, Shanghai 200092, China.
Qing FuTongji University School of Medicine, Shanghai 200092, China.
Jiwen ZhuDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Xi YueDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Runzhi HuangTongji University School of Medicine, Shanghai 200092, China.ORCID https://orcid.org/0000-0003-2302-7305
Enbo QiDepartment of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.ORCID https://orcid.org/0000-0002-5242-2884
Zongqiang HuangDepartment of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.ORCID https://orcid.org/0000-0002-2787-1629
Tongji University · CNFirst Affiliated Hospital of Zhengzhou University · CNHunan Cancer Hospital · CNSecond Military Medical University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas including astrocytomas, oligodendrogliomas, mixed oligoastrocytic, and mixed glioneuronal tumors are an important group of brain tumors. Based on the 2016 WHO classification for tumors in the central nervous system, gliomas were classified into four grades, from I to IV, and brain lower grade glioma (LGG) consists of grade II and grade III. Patients with LGG may undergo recurrence, which makes clinical treatment tough. Stem cell-like features of cancer cells play a key role in tumor's biological behaviors, including tumorigenesis, development, and clinical prognosis. In this article, we quantified the stemness feature of cancer cells using the mRNA stemness index (mRNAsi) and identified stemness-related key genes based on correlation with mRNAsi. Besides, hallmark gene sets and translate factors (TFs) which were highly related to stemness-related key genes were identified. Therefore, a recurrency-specific network was constructed and a potential regulation pathway was identified. Several online databases, assay for transposase-accessible chromatin using sequencing (ATAC-seq), single-cell sequencing analysis, and immunohistochemistry were utilized to validate the scientific hypothesis. Finally, we proposed that aurora kinase A (AURKA), positively regulated by Non-SMC Condensin I Complex Subunit G (NCAPG), promoted E2F target pathway in LGG, which played an important role in LGG recurrence.

Indexed as

AstrocytomaBrain NeoplasmsGliomaBrainHumansPrognosis

Identifiers

PMID36703644
PMCPMC9873439
OpenAlexW4317038194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.